I54.F BIOCYTOGEN PHARMA. H YC1
- Market cap
- EUR 2.22B
- P/E
- 50.0x
- P/B
- 6.71x
- ROE
- 8.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is I54.F undervalued?
Graham numberThe Graham number of BIOCYTOGEN PHARMA. H YC1 cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOCYTOGEN PHARMA. H YC1 fundamental analysis
No fundamental analysis for BIOCYTOGEN PHARMA. H YC1 yet.
BIOCYTOGEN PHARMA. H YC1 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs …
Full company profileBIOCYTOGEN PHARMA. H YC1 financial statements
BIOCYTOGEN PHARMA. H YC1 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 355M | 534M | 717M | 980M | 1.38B |
| Gross Profit | 247M | 392M | 506M | 762M | 1.05B |
| Operating Income | -529M | -602M | -301M | 150M | 279M |
| EBITDA | - | -371M | -97.9M | 304M | 419M |
| Net Income | -546M | -602M | -383M | 33.5M | 173M |
| EPS | -1.38 | -1.51 | -0.96 | 0.08 | 0.39 |
| Balance Sheet | |||||
| Total Assets | 2.30B | 2.80B | 2.45B | 2.42B | 3.72B |
| Total Liabilities | 1.05B | 1.65B | 1.66B | 1.58B | 1.54B |
| Shareholders' Equity | 1.25B | 1.15B | 786M | 834M | 2.17B |
| Cash & Short-term Investments | 466M | 603M | 400M | 381M | 1.56B |
| Cash Flow | |||||
| Operating Cash Flow | -366M | -303M | -76.6M | 211M | 370M |
| Capital Expenditure | 199M | 240M | 127M | 37.1M | 87.8M |
| Free Cash Flow | -564M | -544M | -203M | 174M | 282M |
| Ratios | |||||
| ROE | -43.7% | -52.5% | -48.7% | 4.0% | 8.0% |
| ROA | -23.7% | -21.5% | -15.6% | 1.4% | 4.7% |
| Net Profit Margin | -153.9% | -112.7% | -53.4% | 3.4% | 12.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOCYTOGEN PHARMA. H YC1 dividends
BIOCYTOGEN PHARMA. H YC1 has not paid dividends in the last 5 fiscal years.
Who owns BIOCYTOGEN PHARMA. H YC1
- Insiders 24.32%
- Institutions 55.76%
- Public & others 19.92%
- Shares outstanding 108M
- Free float 155M
BIOCYTOGEN PHARMA. H YC1 company profile
- Company name
- BIOCYTOGEN PHARMA. H YC1
- Ticker
- I54.F
- ISIN
- CNE100005D27
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,443
- Fiscal year end
- December
- Address
- 12 Baoshen South Street, Beijing, China
- Phone
- 86 10 5696 7680
- Website
- biocytogen.com
About BIOCYTOGEN PHARMA. H YC1
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People's Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provides the pre-clinical pharmacology service for drug efficacy and toxicity evaluation; engages in breeding and selling animal models for the external and internal use, including set of genetically engineered mice, disease mouse models and aged small animals; engages un utilizing the Group's own antibody discovery platforms to identify antibodies which have the potential to become drug candidates; and engages in research and development of innovative drugs with a focus on oncology and autoimmune disease therapeutics. The company also offers YH001, a recombinant humanized anti-cytotoxic t-lymphocyte associated protein 4 immunoglobulin G1 (IgG1) monoclonal antibody for the treatment of patients with advanced solid tumors; It also develops YH002, a recombinant humanized IgG1 antibody that targets the human tumor necrosis factor receptor superfamily, member 4 receptor, which is Phase I clinical trial. The company has collaboration with Syncromune, Inc.; a license agreement with RemeGen Co., Ltd.; license agreement with Chipscreen NewWay Biosciences. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was founded in 2008 and is headquartered in Beijing, China.
BIOCYTOGEN PHARMA. H YC1 management
8- Dr. Yuelei Shen Ph.D.Chairman of the Board, CEO & GM · born 1969
- Dr. Jian NiExecutive Director · born 1971
- Mr. Bin LiuChief Financial Officer · born 1968
- Dr. Yi YangChief Scientific Officer & Deputy GM · born 1978
- Ms. Chunli SunDirector of Human Resources · born 1980
- Dr. Qingcong LinDeputy GM & CEO of Biocytogen Boston Corp. · born 1965
- Mr. Yongliang WangDeputy GM & Secretary · born 1985
- Ms. Wai Ching Au A.C.I.S.Joint Company Secretary · born 1976